Global endometrial cancer therapeutics market is expected to witness significant growth as there are
less number of approved drugs for treatment of endometrial cancer, leading to
an increased opportunity for the drug manufacturers. High prevalence of cancer
and rising demand for safe and effective medications can be attributed as the
major drivers of this market. The regulatory bodies such as USFDA and EMA are
supporting the growth of the global market by providing increased funding,
designations and grants for speeding up the drug development process.
Endometrial cancer is the malignancy that develops in the
layers of the cells that forms endometrium, lining of uterus. The precise cause
of endometrial cancer is still unknown but it is assumed that estrogen may be
involved in developing endometrial cancer, as estrogen helps in the formation
of the endometrial lining. Obesity, polycystic ovary syndrome, infrequent
periods and history of endometrial polyps can increase the risk of endometrial
cancer. Women with diabetes, high blood pressure or breast cancer are at a
greater risk of having endometrial cancer. Abnormal vaginal bleeding, bleeding
between periods or after menopause, lower abdominal cramps or clear vaginal
discharge after menopause are some of the main symptoms of endometrial cancer.
High prevalence and recurrence of endometrial cancer
after treatment with chemotherapy are the major driving factors driving the
endometrial cancer therapeutic market. Growing prevalence of obesity in
women aged 50 years or above is also contributing in the growth of the
endometrial cancer therapeutics market globally. Apart from this, safety
concerns after chemotherapy, hormone therapy and radiation therapy restrict the
medications for the treatment of endometrial cancer.
Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=endometrial-cancer-treatment-market
Geographically,
North America is expected to be the largest market for endometrial cancer
therapeutics treatment, owing to the large number of research and development
activities ad high healthcare expenditure. Europe is expected to hold the
second largest share in the global market owing to growing product availability
in the region.
Some of the
key players operating in the global endometrial cancer therapeutics market are
AstraZeneca Plc., Novartis AG, Bristol-Myers Squibb Company, Pfizer, Inc. and
R-Pharm-US LLC.
